KINSTEDO Trademark

Trademark Overview


On Wednesday, July 6, 2022, a trademark application was filed for KINSTEDO with the United States Patent and Trademark Office. The USPTO has given the KINSTEDO trademark a serial number of 97491606. The federal status of this trademark filing is REVIVED - AWAITING FURTHER ACTION as of Tuesday, October 7, 2025. This trademark is owned by Auspex Pharmaceuticals, Inc.. The KINSTEDO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
kinstedo

General Information


Serial Number97491606
Word MarkKINSTEDO
Filing DateWednesday, July 6, 2022
Status616 - REVIVED - AWAITING FURTHER ACTION
Status DateTuesday, October 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 3, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 26, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAUSPEX PHARMACEUTICALS LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressPARSIPPANY, NJ 07054

Party NameAuspex Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameAuspex Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Wednesday, November 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, July 9, 2022NEW APPLICATION ENTERED
Tuesday, July 26, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 23, 2022ASSIGNED TO EXAMINER
Wednesday, December 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 22, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, August 16, 2023SOU EXTENSION 1 GRANTED
Tuesday, January 3, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 28, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 16, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 16, 2023SOU EXTENSION 1 FILED
Tuesday, February 27, 2024SOU EXTENSION 2 FILED
Tuesday, February 27, 2024SOU EXTENSION 2 GRANTED
Tuesday, February 27, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 19, 2024SOU EXTENSION 3 GRANTED
Monday, August 19, 2024SOU EXTENSION 3 FILED
Wednesday, January 22, 2025SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 11, 2025AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, September 29, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, September 30, 2025PETITION TO REVIVE-GRANTED
Tuesday, September 30, 2025NOTICE OF REVIVAL - E-MAILED
Tuesday, September 30, 2025TEAS PETITION TO REVIVE RECEIVED
Tuesday, September 30, 2025SOU EXTENSION RECEIVED WITH TEAS PETITION
Monday, September 29, 2025ABANDONMENT - NO USE STATEMENT FILED
Wednesday, January 22, 2025SOU EXTENSION 4 FILED
Wednesday, January 22, 2025SOU EXTENSION 4 GRANTED
Tuesday, March 4, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED